p53、p16在胆囊癌的表达及其临床意义

本研究应用免疫组化ABC法对53例胆囊癌组织及因其他疾病手术切除的正常胆囊组织15例(均经病理证实)进行了p53、p16基因产物的联合检测。结果:p53基因改变发生于胆囊肿瘤的早期,临床Ⅳ期和低分化腺癌的的表达水平分别高于Ⅰ期和高分化腺癌,提示p53的检测可能作为胆囊肿瘤预后及腺癌恶性程度判断的潜在指标。p16表达的改变主要发生在肿瘤的中、晚期,可能与肿瘤的转移和腺癌恶性程度有关,对判断肿瘤转移倾向有一定帮助。联合检测p53、p16可提高对肿瘤的生物学特性的反映。

The expression of p52,p16 and their relationship with the clinic significance in gallbladder carcinomas

The expression of genes p53 p16 were analyzed by immunohistochemical techniques in 53 cases of gallbladder carcinoma and 15 cases of normal gallbladder which had been pathologically proved. Alterations of p53 gene are early events in carcinogenesis. Abnormalities of p53 may be closely associated with clinical stage of turner , grade of adencarcinomas, so the overexpression of p53 protein may be a potential indicator of poor prognosis, grade of adenocarcimas. Alterations of p16 are later stage of turner, indicating abnormalities of p16 may be associated with progress,metastasis. These abnormality may be a predictor of tendency of metastasis. detection of both p53 and ras p21 may raise a ability to predict bioligical activity of the carcinomas.